PMC:7161517 / 16470-16784 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T99","span":{"begin":60,"end":66},"obj":"Body_part"},{"id":"T100","span":{"begin":103,"end":109},"obj":"Body_part"}],"attributes":[{"id":"A99","pred":"fma_id","subj":"T99","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A100","pred":"fma_id","subj":"T100","obj":"http://purl.org/sig/ont/fma/fma62970"}],"text":"Treatment with ramipril and valsartan resulted in increased plasma Ang I and Ang II and suppression in plasma ACE and ACE2 activity; however, neither monotherapy nor combination therapy affected ACE2 or AT1 receptor expression, both of which remained at levels comparable to non-myocardial infarction control (47)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T70","span":{"begin":203,"end":206},"obj":"Disease"},{"id":"T71","span":{"begin":279,"end":300},"obj":"Disease"}],"attributes":[{"id":"A70","pred":"mondo_id","subj":"T70","obj":"http://purl.obolibrary.org/obo/MONDO_0008840"},{"id":"A71","pred":"mondo_id","subj":"T71","obj":"http://purl.obolibrary.org/obo/MONDO_0005068"}],"text":"Treatment with ramipril and valsartan resulted in increased plasma Ang I and Ang II and suppression in plasma ACE and ACE2 activity; however, neither monotherapy nor combination therapy affected ACE2 or AT1 receptor expression, both of which remained at levels comparable to non-myocardial infarction control (47)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T167","span":{"begin":60,"end":66},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T168","span":{"begin":103,"end":109},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T169","span":{"begin":123,"end":131},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"Treatment with ramipril and valsartan resulted in increased plasma Ang I and Ang II and suppression in plasma ACE and ACE2 activity; however, neither monotherapy nor combination therapy affected ACE2 or AT1 receptor expression, both of which remained at levels comparable to non-myocardial infarction control (47)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T213","span":{"begin":15,"end":23},"obj":"Chemical"},{"id":"T214","span":{"begin":28,"end":37},"obj":"Chemical"},{"id":"T215","span":{"begin":81,"end":83},"obj":"Chemical"}],"attributes":[{"id":"A213","pred":"chebi_id","subj":"T213","obj":"http://purl.obolibrary.org/obo/CHEBI_8774"},{"id":"A214","pred":"chebi_id","subj":"T214","obj":"http://purl.obolibrary.org/obo/CHEBI_9927"},{"id":"A215","pred":"chebi_id","subj":"T215","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"}],"text":"Treatment with ramipril and valsartan resulted in increased plasma Ang I and Ang II and suppression in plasma ACE and ACE2 activity; however, neither monotherapy nor combination therapy affected ACE2 or AT1 receptor expression, both of which remained at levels comparable to non-myocardial infarction control (47)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T106","span":{"begin":0,"end":314},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Treatment with ramipril and valsartan resulted in increased plasma Ang I and Ang II and suppression in plasma ACE and ACE2 activity; however, neither monotherapy nor combination therapy affected ACE2 or AT1 receptor expression, both of which remained at levels comparable to non-myocardial infarction control (47)."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T19","span":{"begin":279,"end":300},"obj":"Phenotype"}],"attributes":[{"id":"A19","pred":"hp_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/HP_0001658"}],"text":"Treatment with ramipril and valsartan resulted in increased plasma Ang I and Ang II and suppression in plasma ACE and ACE2 activity; however, neither monotherapy nor combination therapy affected ACE2 or AT1 receptor expression, both of which remained at levels comparable to non-myocardial infarction control (47)."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T620","span":{"begin":15,"end":23},"obj":"CHEBI:8774;CHEBI:8774"},{"id":"T621","span":{"begin":60,"end":66},"obj":"UBERON:0001969"},{"id":"T622","span":{"begin":67,"end":70},"obj":"CHEBI:29101;CHEBI:29101;PR:000036008"},{"id":"T623","span":{"begin":71,"end":72},"obj":"PR:000036008;CHEBI:16382;CHEBI:16382"},{"id":"T624","span":{"begin":77,"end":83},"obj":"PR:000036009"},{"id":"T625","span":{"begin":103,"end":109},"obj":"UBERON:0001969"},{"id":"T626","span":{"begin":118,"end":122},"obj":"PR:000003622;G_3;PG_10"},{"id":"T627","span":{"begin":195,"end":199},"obj":"PR:000003622;G_3;PG_10"},{"id":"T628","span":{"begin":203,"end":206},"obj":"PR:000001251"},{"id":"T629","span":{"begin":216,"end":226},"obj":"GO:0010467"},{"id":"T630","span":{"begin":279,"end":289},"obj":"UBERON:0002349"},{"id":"T74716","span":{"begin":2,"end":13},"obj":"CHEBI:9434;CHEBI:9434"},{"id":"T88764","span":{"begin":29,"end":36},"obj":"UBERON:0000948"},{"id":"T80829","span":{"begin":37,"end":41},"obj":"G_3;PG_10;PR:000003622"},{"id":"T65771","span":{"begin":51,"end":58},"obj":"BV_20"},{"id":"T58470","span":{"begin":59,"end":69},"obj":"BV_20;GO:0010467"},{"id":"T72678","span":{"begin":87,"end":93},"obj":"UBERON:0001969"},{"id":"T79500","span":{"begin":94,"end":98},"obj":"PR:000036013"},{"id":"T87382","span":{"begin":143,"end":150},"obj":"UBERON:0000948"},{"id":"T91462","span":{"begin":244,"end":254},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T59581","span":{"begin":285,"end":289},"obj":"G_3;PG_10;PR:000003622"},{"id":"T32923","span":{"begin":290,"end":300},"obj":"GO:0010467"}],"text":"Treatment with ramipril and valsartan resulted in increased plasma Ang I and Ang II and suppression in plasma ACE and ACE2 activity; however, neither monotherapy nor combination therapy affected ACE2 or AT1 receptor expression, both of which remained at levels comparable to non-myocardial infarction control (47)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"710","span":{"begin":110,"end":113},"obj":"Gene"},{"id":"711","span":{"begin":118,"end":122},"obj":"Gene"},{"id":"712","span":{"begin":195,"end":199},"obj":"Gene"},{"id":"729","span":{"begin":67,"end":70},"obj":"Gene"},{"id":"737","span":{"begin":77,"end":80},"obj":"Gene"},{"id":"742","span":{"begin":15,"end":23},"obj":"Chemical"},{"id":"743","span":{"begin":28,"end":37},"obj":"Chemical"},{"id":"751","span":{"begin":279,"end":300},"obj":"Disease"}],"attributes":[{"id":"A710","pred":"tao:has_database_id","subj":"710","obj":"Gene:24310"},{"id":"A711","pred":"tao:has_database_id","subj":"711","obj":"Gene:302668"},{"id":"A712","pred":"tao:has_database_id","subj":"712","obj":"Gene:302668"},{"id":"A729","pred":"tao:has_database_id","subj":"729","obj":"Gene:283"},{"id":"A737","pred":"tao:has_database_id","subj":"737","obj":"Gene:283"},{"id":"A742","pred":"tao:has_database_id","subj":"742","obj":"MESH:D017257"},{"id":"A743","pred":"tao:has_database_id","subj":"743","obj":"MESH:D000068756"},{"id":"A751","pred":"tao:has_database_id","subj":"751","obj":"MESH:D009203"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Treatment with ramipril and valsartan resulted in increased plasma Ang I and Ang II and suppression in plasma ACE and ACE2 activity; however, neither monotherapy nor combination therapy affected ACE2 or AT1 receptor expression, both of which remained at levels comparable to non-myocardial infarction control (47)."}

{"project":"2_test","denotations":[{"id":"32305401-22715807-55252961","span":{"begin":310,"end":312},"obj":"22715807"}],"text":"Treatment with ramipril and valsartan resulted in increased plasma Ang I and Ang II and suppression in plasma ACE and ACE2 activity; however, neither monotherapy nor combination therapy affected ACE2 or AT1 receptor expression, both of which remained at levels comparable to non-myocardial infarction control (47)."}